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ABSTRACT
Sipuleucel-T is the only FDA-approved immunotherapy for metastatic castration-resistant prostate
cancer. The mechanism by which this treatment improves survival is not fully understood. We have
previously shown that this treatment can induce the recruitment of CD4 and CD8 T cells to the tumor
microenvironment. In this study, we examined the functional state of these T cells through gene
expression profiling. We found that the magnitude of T cell signatures correlated with the frequency
of T cells as measured by immunohistochemistry. Sipuleucel-T treatment was associated with increased
expression of Th1-associated genes, but not Th2-, Th17 – or Treg-associated genes. Post-treatment
tumor tissues with high CD8+T cell infiltration was associated with high levels of CXCL10 expression. On
in situ hybridization, CXCL10+ cells colocalized with CD8+T cells in post-treatment prostatectomy tumor
tissue. Neoadjuvant sipuleucel-T was also associated with upregulation of immune inhibitory check-
points, including CTLA4 and TIGIT, and downregulation of the immune activation marker, dipeptidyl-
peptidase, DPP4. Treatment-associated declines in serum PSA were correlated with induction of Th1
response. In contrast, rises in serum PSA while on treatment were associated with the induction of
multiple immune checkpoints, including CTLA4, CEACAM6 and TIGIT. This could represent adaptive
immune resistance mechanisms induced by treatment. Taken together, neoadjuvant sipuleucel-T can
induce both a Th1 response and negative immune regulation in the prostate cancer microenvironment.
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Introduction
Sipuleucel-T (Provenge) is an autologous cellular vaccine
approved for the treatment of metastatic castration resis-
tant prostate cancer in patients who have asymptomatic
or minimally symptomatic disease. Sipuleucel-T is
designed to stimulate an anti-tumor immune response
against prostatic acid phosphatase (PAP), a tumor-asso-
ciated antigen expressed in over 95% of prostate adeno-
carcinoma. It was recently appreciated that sipuleucel-T
also induces humoral immune responses against non-tar-
get (non-PAP) tumor antigens via antigen spread1 and
this broadening of the immune response may contribute
to the clinical efficacy of sipuleucel-T in the extension of
overall survival.2,3
To investigate the effect of sipuleucel-T in the tumor micro-
environment, we had conducted a phase II study of neoadjuvant
sipuleucel-T in patients prior to radical prostatectomy.
Immunohistochemical analysis showed that neoadjuvant sipu-
leucel-T induced T cell infiltration into the tumor (CD8+ >
CD4+FOXP3− > CD4+FOXP3+) with an activated phenotype
(CD3+Ki67+, CD3+PD-1+) at the tumor interface4 More
recently, utilizing deep sequencing of the TCRβ CD3 region in
the same patient cohort, we showed that neoadjuvant sipuleucel-
T decreased the diversity of circulating TCR repertoire while
increased the diversity of TCR repertoire in the tumor tissue.
This resulted in a greater overlap between the peripheral and
intratumoral TCR sequences, which may represent recruitment
of antigen-specific T cells from the periphery into the tumor
tissue.5
In the present study, we investigate functional capacity
intratumoral immune cell populations in paired pre-treatment
biopsy and post-treatment radical prostatectomy tissues. We
show that sipuleucel-T upregulates multiple immune response
categories, including promotion of a Th1 biased immune
response as well as upregulation of immune checkpoint sup-
pressors which are associated with divergent treatment-asso-
ciated PSA changes.
Results
Neoadjuvant sipuleucel-T treatment induces a T cell
expression profile in the tumor microenvironment
We examined the expression profile of formalin fixed par-
affin embedded (FFPE) prostate tissues obtained pre- or
CONTACT Lawrence Fong lfong@medicine.ucsf.edu University of California San Francisco, 513 Parnassus Avenue, Room HSE301A, Box 0519, San
Francisco, CA
Supplemental data for this article can be accessed here.
ONCOIMMUNOLOGY
2019, VOL. 8, NO. 1, e1486953 (6 pages)
https://doi.org/10.1080/2162402X.2018.1486953
© 2019 The Author(s). Published with license by Taylor & Francis Group, LLC
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
post-sipuleucel-T treated using the nCounter PanCancer
Immune panel (Nanostring). Most genes in the panel
appeared to be upregulated after treatment with sipuleu-
cel-T, consistent with stimulation of an intratumoral
immune response with treatment (Figure 1A). Upon closer
examination, all immune response categories appeared to
be upregulated after treatment with sipuleucel-T, with
genes involved in leukocyte functions exhibiting the highest
level of increase in expression (Figure 1B). Immune cell
scores of lymphocytes infiltrated into the tumor microen-
vironment were calculated by nSolver software based on
gene expression levels normalized to housekeeping genes6
The scores of total T cells, cytotoxic CD8 T cells, and
helper T cells were significantly increased after sipuleucel-
T treatment (p = 0.02, 0.05 and <0.01, respectively), and
there was a trend for increased total B cells post-treatment
(p = 0.11, Figure 1C). When examining specific CD4 T cell
subsets, the immune cell score of the Th1 subtype was
significantly increased after treatment (p = 0.03), while
the immune cell scores of Th2, Th17 and Treg subtypes
were unchanged (Figure 1D). For all five paired cases
examined, an upregulation of Th1/Th2 ratio was observed
with treatment (p < 0.01, Figure 1E). We had previously
shown that sipuleucel-T treatment was associated with an
increase in infiltration of CD3+, CD4+Foxp3- and CD8+T
cells into the tumor microenvironment4 To confirm relia-
bility of the calculated lymphocyte scores, we assessed their
correlation with CD3, CD8, Foxp3 and CD20 staining by
immunohistochemistry (IHC), scored by the frequency of
positive staining at the tumor interface. The total T cells,
CD8 T cells and Treg scores were significantly correlated
with IHC scores for CD3, CD8 and Foxp3, respectively
(p = 0.02). There was a trend in correlation between the
B cell score and CD20 staining on IHC (p = 0.08)
(Supplemental Figure 1).
Chemokine changes associated with high intratumoral
CD8+T cell infiltration following sipuleucel-T treatment
We hypothesized that chemokines produced in the tumor
microenvironment served to attract CD8+T cells into the
tumor and sought to identify chemokine genes differentially
upregulated in high CD8+T cell infiltrated versus low CD8+T
cell infiltrated post-treatment prostatectomy tumor tissues
(N = 14). We found that CXCL10 was the most significantly
differentially upregulated gene, followed by CXCL9 and
CXCL11 (Figure 2A), suggesting that these cytokines – parti-
cularly CXCL10 – may promote the migration of CD8 T cells
into the tumor microenvironment. To further investigate this
possibility, we performed in situ hybridization in post-sipu-
leucel-T tumor tissues. CD8a expressing cells were localized
close to CXCL10 expressing cells in the tumor microenviron-
ment (Figure 2B), supporting its role in the attraction of CD8
+T cells. M1 macrophages have been reported to produce
CXCL10.7 In keeping with this, the expression levels of
genes associated with M1 macrophages (CD68, CD80 and
CD86) were significantly correlated with CXCL10 gene
expression (Supplemental Figure 2).
Serum PSA decline is associated with induction of Th1
response after sipuleucel-T treatment
We examined the association between treatment-related PSA
change and immune cell scores determined by gene expres-
sion (Supplemental Table 1), where the data of PSA change
were available in thirteen cases. Six (43%) patients had PSA
decline with sipuleucel-T treatment (range of PSA decline:
5.3%–33.6%). Maximal PSA change was inversely correlated
with Th1/total T cell ratio (Figure 3A), suggesting that infil-
tration of Th1 cells into the tumor microenvironment pro-
motes PSA response. We also examined the modulation of
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Figure 1. Gene expression of paired prostate tissues obtained pre- and post-sipuleucel-T treatment. (A) Post-sipuleucel-T vs. pre-sipuleucel-T gene expression
analysis. Heatmap of the unsupervised clustering of normalized genes expressed, scaled to give all genes equal variance. Orange indicates high expression; blue
indicates low expression. (B) Directed global significance immune cell scores (post-sipuleucel-T vs. pre-sipuleucel-T). The score values were calculated as the square
root of the mean signed squared t-statistic for the genes in a gene set, with t-statistics derived from the linear regression underlying the differential expression
analysis. (C) Immune gene scores of T cells, CD8+T cells, Th cells and B cells in prostate tumor tissues before and after sipuleucel-T treatment. Two-tailed paired t test
was used to test for differences in mean Nanostring scores. (D) Scores of T cell subsets in prostate tumor tissues before and after sipuleucel-T treatment. Each T cell
subset score was calculated based on the following genes; Th1 cells: CTLA4, LTA, IFNG, CD38, and CCL4; Th2 cells: PMCH; Th17 cells: IL26 and IL17A; Treg cells: FOXP3
and LILRA4. Two-tailed paired t test was used to test for differences in mean Nanostring scores. (E) Comparison of Th1/Th2 score ratios between pre- and post-
sipuleucel-T treatment. Two-tailed paired t test was used to test for differences in mean Nanostring score ratios. (F) Correlation of immune cell scores by gene
expression (X-axis) with IHC scores (Y-axis). For the IHC scores, CD3+, CD8+, Foxp3+ and CD20+ cells were quantified by digital image analysis at the tumor interface.
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PSA transcripts in patients with paired tissues obtained pre-
and post-sipuleucel-T treatment. Because Th1 immune cell
score was significantly correlated with CD8 T cell score
(P = 0.01, Figure 3B), we hypothesize that both T cell subtypes
are enriched in the tumor microenvironment of patients who
had PSA response during neoadjuvant sipuleucel-T treatment.
Serum PSA increase is associated with transcriptional
induction of inhibitory checkpoint genes after treatment
Even though immune cell score for Th1 cells were induced by
sipuleucel-T, tumor infiltration by total T cells in post-treat-
ment tissue was associated with PSA increase in serum
(p = 0.02) (Figure 4A). We hypothesized that a proportion
of the observed T cells were of a regulatory or exhausted
phenotype, rather than of an activated phenotype. Indeed,
there was also a trend of association between regulatory T
cells and PSA increase in serum (p = 0.10) (Figure 4B). To this
end, we performed differential expression gene analysis of the
five paired pre- and post-sipuleucel-T treated tumor tissues,
focusing on T cell function-related genes. The inhibitory
checkpoint genes CTLA4, TIGIT, and CEACAM6 were upre-
gulated by sipuleucel-T treatment, while the T cell functional
marker DPP4 was downregulated (Figure 4C). The level of
gene expression of these inhibitory checkpoints in post-treat-
ment RP tumors (N = 14) were significantly correlated with
an increase in serum PSA after treatment (n = 14), (p = 0.01,
<0.05 and 0.02 for CTLA4, TIGIT and CEACAM6, respec-
tively, Figure 4D). These data suggest that the expression of
these inhibitory checkpoint genes may hinder immune-
mediated anti-tumor activity with sipuleucel-T treatment.
Discussion
We have previously shown that activated T cells are recruited
into the prostate tumor microenvironment by sipuleucel.4 We
now show that neoadjuvant sipuleucel-T elicits Th1 response
that includes CXCL10 and a CD8 expression signature. To
our knowledge, this is the first report to confirm that intra-
tumoral Th1 immune response are specifically induced by
sipuleucel-T treatment and are consistent with the Th1
immune responses that have been detected in the circulating
Negative control
Positive control
A. B.
Figure 2. Intratumoral chemokine expression after sipuleucel-T treatment (n = 14). (A) Differential expression of immune-related genes in high vs. low CD8 T cell
infiltrated cases are shown. Chemokine-related genes are shown in red. The X-axis represents log fold-difference which estimates a gene’s differential expression (2^
(log fold change)-fold). (B) Localization of CXCL10 mRNA (green) and CD8a mRNA (red) expressing cells in the tumor microenvironment. The following probes were
used in in situ hybridization. Negative control: DapB (bacterial dihydrodipicolinate reductase); positive control (green): POLR2A (encoding DNA-directed RNA
polymerase II subunit RPB1); positive control (red): PPIB (human peptidylprolyl isomerase B). The section stained for CXCL10/CD8a is representative of fourteen cases.
B.A.
Figure 3. Association between serum PSA change on treatment and intratumoral Th1 score. (A) Correlation between serum PSA change and Th1/T immune gene
score ratio in sipuleucel-T treated patients (n = 13) is shown. (B) Correlation between Th1 and CD8 immune cell scores in tumors from sipuleucel-T treated patients
(n = 14).
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T cells. Despite the induction of a Th1 signature, the induc-
tion of IFN-gamma was relatively modest, especially relative
to the induction of CTLA4. This could reflect the kinetics of
the response as surgical resection was performed 2–3 weeks
following treatment. Alternatively, this blunted IFN-gamma
response could reflect the immunosuppressive environment
or induced immune checkpoints. Indeed, we have shown that
lymphocytes induced by sipuleucel-T are localized are
excluded from the tumor center.4 This phenotype can be
associated with a TGF-beta signature in bladder cancer.8
While that presence of Th1 response associates with a PSA
decrease on treatment, induction of inhibitory checkpoints
was associated with PSA rise on treatment. We found a
trend toward a positive correlation between TGFB1 and PSA
change (r = 0.465, p = 0.1150). Interestingly, TGFB1 was
positively correlated with CD8 cells (r = 0.7143, p = 0.0054).
This could also reflect a mechanism of adaptive resistance.
Gene expression signatures associated with immune and/or
clinical responses in other cancer types include different che-
mokines that contribute to T cell localizatio.9–11 Recently,
Muthuswamy et al. reported that intratumoral CD8 T cells
in untreated prostate tumors were positively correlated with
CXCL9 and CXCL10 levels in the tumor microenvironmen.12
Consistent with this, we found that CXCL9 and CXCL10 are
highly expressed in CD8-infiltrated prostate tumors following
sipuleucel-T treatment. Furthermore, in situ hybridization
showed CXCL10 mRNA expressing cells to be well colocalized
with CD8 T cells. CXCL10 has been shown to be produced by
M1 cells.7 Our data supported this report (Supplementary
Figure 2); however, it remains to be further studied whether
M1 cells actually secrete such functional chemokines. If this is
the case, M1 cells could help convert prostate cancer from the
prototypical cold tumor into a T cell inflamed tumor. Overall,
these findings suggest sipuleucel-T treatment enhances
CXCL9 and CXCL10 production, which in turn promote
CD8 T cell recruitment into the tumor microenvironment.
In these exploratory analyses, we found that the induction of an
intratumoral Th1 expression signature was inversely correlated
with PSAprogression suggesting that Th1 induction by sipuleucel-
T couldmodulate PSA response. On the other hand,we also found
that upregulation of the genes of inhibitory checkpoints CTLA-4,
TIGIT and CEACAM6 were positively correlated with PSA pro-
gression, suggesting the possible role of these checkpoints in
dampening treatment-induced immune responses. These could
represent adaptive resistance mechanisms that could be targeted.
The significance of PSAmodulation observed in this study, which
D.B.
C.
Figure 4. Association between serum PSA change during treatment and induction of inhibitory checkpoint genes in the tumor. (A) Correlation between intratumoral
T cell immune gene score and serum PSA change is shown (n = 13). (B) Correlation between Treg cell immune gene score in the tumor and serum PSA change while
on treatment is shown. (C) Differential expression of immune-related genes in post- vs. pre-sipuleucel-T prostate tumor tissues is shown (n = 5). T cell function-
related genes are highlighted in blue. The X-axis indicates the log fold-change which estimates a gene’s differential expression. (D) Correlation between serum PSA
change and transcript levels of CTLA4, TIGIT and CEACAM6 in post-sipuleucel-T tumor are shown (n = 13).
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were not large in magnitude, is unknown. Moreover, the overall
number of patient samples examined was limited. Nevertheless,
these results provide some rationale for clinical trials combining
sipuleucel-T with immune checkpoint inhibition for prostate can-
cer, including the ongoing clinical trial combining sipuleucel-T
with CTLA-4 blockade for metastatic castration resistant prostate
cancer (NCT01804465). Continued correlative and mechanistic
studies are needed to guide the design of clinical trials utilizing the
most rationale combination strategies.
Materials and methods
Patients
Tissue samples were derived from a single-arm, multicenter
phase II trial of neoadjuvant sipuleucel-T treatment in men
with localized prostate cancer administered prior to planned
R.4 Eligible patients had a normal complete blood count,
adequate hepatic and renal function, tissue available from a
pretreatment prostate biopsy, and were negative for HIV,
HTLV-1 and −2, and hepatitis B and C. All subjects gave
written informed consent to participate in the protocol
approved by the Institutional Review Boards (IRBs) of each
participating institution (NCT00715104). Subjects received
sipuleucel-T at the standard two-week intervals for three
planned doses prior to RP. Sipuleucel-T was started six to
seven weeks prior to RP, allowing for a two- to three-week
interval between the final infusion of sipuleucel-T and the RP.
Gene expression
RNA was extracted from FFPE tumor biopsy and RP sections
using PureLink™ FFPE Total RNA Isolation Kit (Invitrogen) and
was evaluated for gene expression using the nCounter®
PanCancer Immune Profiling Panel (NanoString Technologies,
Inc.), which interrogates 770 immune-related genes and asso-
ciated controls. NanoString gene expression values were normal-
ized using housekeeping genes included in the panel. The nSolver
software (version 3.0) was used to perform all normalization,
analyze gene expression, and calculate immune cell scores.
Normalization was performed using the following house-keep-
ing genes; PRPF38A, HPRT1, AGK, DDX50, HDAC3, TUBB,
TLK2, AMMECR1L, CNOT10, TBP, MTMR14, ZKSCAN5,
USP39, HX16, TMUB2, SF3A3, CNOT4, MRPS5, COG7,
DNAJC14, ABCF1, ERCC3, EIF2B4, ZNF346, POLR2A, FCF1,
PPIA, SDHA, ZC3H14, ALAS1, G6PD, TRIM39, NOL7,
NUBP1, EDC3, SAP130, ZNF143, GUSB, CC2D1B,
GPATCH3. Scores for each cell type were calculated based on
the expression of the following genes; T cells: CD3G, CD96,
SH2D1A, CD6, CD3D, LCK, CD2, and CD3E; CD8 cells:
PRF1, D8A, GZMM, CD8B, and FLT3LG; Th cells: ATF2,
NUP107; B cells: TNFRS 17, CD19, MS4A1, and BLK. Genes
were tested for differential expression in response to each
selected covariate. For each gene, a single linear regression was
fit using all selected covariates to predict expression. Genes pre-
viously shown to be characteristic of various immune cell popu-
lations were used to measure these populations’ abundance.6
Immunohistochemistry
Immunohistochemistry was performed using published
methods.4 Stained slides werescanned with an automated
microscope scanner (Aperio Scanscope XT, Aperio, Buffalo
Grove, IL). For RP sections, tissue was designated into three
distinct compartments: benign glands, tumor centers, and
tumor interfaces. Five randomly selected fields (0.25 mm2,
original magnification 20×, 0.5 µm per pixel resolution)
from each compartment were then captured from each slide
with ImageScope software (Aperio). Tumor interfaces were
defined as fields where malignant and benign glands were
present. Automatic cell counts for single- and double-stained
cells were determined for each field with color-specific algo-
rithms in Axiovision software (Zeiss, Peabody, MA). The cell
count for each compartment is reported as the mean for each
of the five quantitated fields.
In situ hybridization
The RNAscope 2.5 duplex detection assays (Advanced Cell
Diagnostics [ACD], Hayward, CA) were manually performed
using target probes to CXCL10 and CD8a on post-sipuleucel-T
RP sections according to themanufacturer’s instruction. TheRNA
probes (Hs-CXCL10 andHs-CD8A-C2)were designed byACD to
hybridize to CXCL10 and CD8a messenger RNA (mRNA) mole-
cules. Probes Hs-POLR2A (encoding DNA-directed RNA poly-
merase II subunit RPB1) and Hs-PPIB (human peptidylprolyl
isomerase B)-C2 from ACD were used as positive controls.
DapB (bacterial dihydrodipicolinate reductase) from ACD was
used as negative control. Briefly, FFPE tissue sections were depar-
affinized and treated with Hydrogen Peroxide (10 min at room
temperature (r.t.)), Target Retrieval (boiling for 15 min), and
Protease Plus (30 min at 40°C) to allow for target probe access.
Target probes were added onto the slides and incubated in the
HybEZ oven (ACD) for 2 hours at 40°C to allow probe hybridiza-
tion to RNA targets. The slides were washed and incubated with a
series of signal amplification solutions; amplification (Amp) 1
(30 min at 40°C), Amp 2 (15 min at 40°C), Amp 3 (30 min at
40°C), Amp 4 (15min at 40°C), Amp 5 (30min at r.t.), andAmp 6
(15 min at r.t.). Signals to CD8a mRNA were generated by chro-
mogenic reaction using Red-A/B (10 min at r.t.). The slides were
washed and additionally amplified; Amp 7 (15min at 40°C), Amp
8 (30min at 40°C), Amp 9 (30min at r.t.), and Amp 10 (15min at
r.t.). Signals to CXCL10 mRNA were generated using Green-A/B
(10 min at r.t.). The slides were counterstained with hematoxylin
andmountedwithVectaMount. The stained slides were examined
by bright field microscopy.
Statistical analysis
Two-tailed paired t-test was used to assess overall differences in
mean IHC results or Nanostring scores between two groups.
The Spearman rank order correlation was used to evaluate the
relationships between Nanostring scores and IHC results. All
statistical tests were two-sided and p < 0.05 was considered
statistically significant. There was no adjustment for multiple
testing issue unless noted in Nanostring gene expression data
analysis. Statistical analysis was performed using GraphPad
ONCOIMMUNOLOGY e1486953-5
Prism version 7.00 for Windows, GraphPad Software, La Jolla
California USA, www.graphpad.com.
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